JULIA CIZESKI: Open Payments
NPI 1629642897 · MANSFIELD CENTER, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$229 in 11 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $229
Food & beverage: $229
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $106 |
| Alkermes, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| ABBVIE INC. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Neos Therapeutics, LP | 1 | $14 |
Products named: INGREZZA, TRINTELLIX, VRAYLAR, AUSTEDO XR, LYBALVI, ARISTADA, EXXUA.
Industry payments across CT — which companies pay providers there.
